[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,1100,0,25,[9,47,79,103,133,169,203,233,274,296,329,354,381,403,423,450,474,501,525,552,573,601,623,650,688],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652807","tacs-and-upper-limb-rehabilitation-in-chronic-stroke-100652807",false,"NCT07778342","tACS and Upper Limb Rehabilitation in Chronic Stroke","Pilot Study Investigating the Neuromodulatory Effects of Transcranial Alternating Current Stimulation (tACS) on Upper Limb Motor Rehabilitation in Chronic Stroke Patients","Inclusion Criteria:\n\n1. Age 21-80 years old;\n2. First ever stroke, at least 9 months after stroke onset;\n3. Evidence of corticomotor excitability as manifested by a recordable Motor Evoked Potential from the ipsilesional Motor Cortex (M1) by TMS measurement.\n4. Objectively documented motor weakness of the upper extremity as manifested by an Upper Extremity-Fugl-Meyer Assessment score \\\u003C=55\n\nExclusion Criteria:\n\n1. Patients with implants: cardiac, neural or medication implants; any electrically, magnetically or mechanically activated implant; brain medical devices; vascular clips or any other electrically sensitive support system in the brain; other metal implants inside the body that are contraindications of MRI scan;\n2. Pregnancy;\n3. Patients with a history of seizures; Patients with unexplained episodes of loss of consciousness, since such condition could be related with brain alterations or epilepsy;\n4. Patients with serious brain injury;\n5. Patients showing damage of skin at sites of stimulation;\n6. Patients with unstable or non-controlled neuropsychiatric illness;\n7. Patients suffering from severe or frequent headaches;\n8. Patients with any serious life-threatening disease such as congestive heart failure, pulmonary obstructive chronic disease or active neoplasia;\n9. Sensorimotor disturbance due to other causes other than stroke;","ALL","21 Years","80 Years",{"count":21,"type":22},34,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study tests whether a brain stimulation technique called tACS can help stroke patients recover movement in their affected arm.\n\nPatients receive either real or fake brain stimulation three times a week for about a month (12 sessions total). During each session, they wear a cap with electrodes that deliver mild electrical currents tailored to their individual brain patterns, while researchers monitor their brain activity.\n\nThe study measures progress at three time points: before treatment, right after treatment, and one month later. Researchers use brain stimulation tests to check how well the brain controls muscles, and conduct physical tests to measure arm movement, muscle stiffness, and grip strength.",[28],"Stroke",[30,31,32,33],"transcranial Alternating Current Stimulation","stroke","upper limb","motor recovery","NOT_YET_RECRUITING","2026-08-20",{"date":37,"type":38},"2026-08-21","ACTUAL",{"date":40,"type":22},"2026-12-01",{"date":42,"type":22},"2028-12-31",{"name":44,"class":45},"National University Hospital, Singapore","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100563423","screening-for-social-determinants-of-health-sdoh-and-cognitive-function-in-individuals-with-history-of-stroke-100563423","NCT06615973","Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke","Understanding Stroke Outcomes: Stroke Resilience, Infarct Burden, and Long-Term Cognition","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Adults aged 18 or older.\n* Previous participant in the Natural History of Stroke with an interpretable baseline MRI scan, NIHSS measured at baseline or discharge, and admission diagnosis of ischemic stroke.\n* Fluent in English or Spanish\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this\n\nstudy:\n\n-Modified Rankin Scale (mRS) = 6 at any follow-up (usually up to 90 days) in the Natural History of Stroke study (mRS = 6 indicates the participant is dead).","18 Years","99 Years",{"count":57,"type":22},450,"OBSERVATIONAL","Background:\n\nStroke is the fifth leading cause of death in the United States. It is also a leading cause of disability. More than 70% of people who survive strokes have mental impairment or dementia. Medical factors, such as the severity of the stroke, affect whether a person will have mental impairment afterward. But social factors, such as education and ethnicity, seem to play a role as well. Researchers want to learn more about how social and lifestyle factors affect a person s chances of maintaining mental functions after a stroke.\n\nObjective:\n\nTo better understand how social and lifestyle factors affect the risk of mental impairment after a stroke.\n\nEligibility:\n\nPeople aged 18 years and older who had a stroke and a brain scan while they were enrolled in NIH Study 01N0007 (Natural History of Stroke Study).\n\nDesign:\n\nParticipants will have 1 study visit, by telephone. The call will last about 45 minutes. Participants will talk about their health since their stroke. They will answer questions about themselves. Topics will include:\n\n* Their race\n* Education\n* Ethnicity\n* Employment\n* Marital status\n* Residence address\n* Recent health history\n* Medical insurance\n\nThey will have tests of their memory, attention, and language skills. They will repeat numbers and words forward and backward.\n\nResearchers will look at the data and imaging scans collected during participant s enrollment in NIH Study 01N0007. This data will include:\n\n* The hospital that first saw the participant at the time of their stroke.\n* The type of imaging that was first used then.\n* The primary diagnosis at admission.\n* Other medical details.",[28,61,62,63],"Brain Disease","Vascular Diseases","Cerebrovascular Disorder",[28,65,66,67,68,69],"Social Determinants of Health","Cognition","cerebrovascular health","Magnetic Resonance Imaging (MRI)","vascular health","RECRUITING",{"date":37,"type":38},{"date":73,"type":22},"2026-08-26",{"date":75,"type":22},"2027-02-01",{"name":77,"class":78},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100652102","transcranial-direct-current-stimulation-for-neurogenic-overactive-bladder-symptoms-among-people-with-stroke-100652102","NCT07768137","Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke","Transcranial Direct Current Stimulation for Neurogenic Overactive Bladder Symptoms Among People With Stroke: a Randomized Controlled Pilot Trial","Inclusion Criteria:\n\n* Aged between 18-80 years with onset of stroke within one and twelve months of enrollment and having overactive bladder (OAB) symptoms;\n* Experiencing moderate (scoring 6-11 points on the Overactive Bladder Symptom Score \\[OABSS\\]) to severe OAB (scoring ≥ 12 points on OABSS);\n* Obtaining a Mini-Mental State Examination (MMSE) score of ≥ 24.\n\nExclusion Criteria:\n\n* Presence of metallic implants in the cranium, intracardiac lines, increased intracranial pressure, cardiac pacemaker, cochlear implants, tumour, and skull abnormalities;\n* Family history of epilepsy\u002Fseizures;\n* Contraindications to transcranial magnetic stimulation.",{"count":87,"type":22},60,[25],"Neurogenic overactive bladder (nOAB) is a common and distressing sequela following stroke, significantly impairing quality of life and imposing a substantial financial burden. Existing pharmacological options often present adverse effects, while standard non-pharmacological treatments, such as pelvic floor muscle training (PFMT), face compliance and efficacy limitations in individuals with functional impairments. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique capable of modulating neuronal excitability and cortical plasticity. Targeting the supplementary motor area (SMA) via tDCS may regulate pelvic floor muscle (PFM) and detrusor activities. However, clinical evidence evaluating tDCS as an adjuvant to PFMT for stroke survivors with nOAB is lacking. This randomized controlled pilot trial aims to evaluate the feasibility, preliminary effectiveness, and cost-utility of active tDCS combined with PFMT compared to sham tDCS plus PFMT in stroke survivors suffering from nOAB.",[28,91],"Neurogenic Overactive Bladder",[93,94,28],"Transcranial direct current stimulation","Overactive bladder","2026-08-19",{"date":37,"type":38},{"date":98,"type":22},"2026-09-14",{"date":100,"type":22},"2027-12-31",{"name":102,"class":45},"The Hong Kong Polytechnic University",{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":113,"conditions":114,"keywords":122,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":46},"100525407","precision-medicine-in-stroke-evolution-of-plasma-brain-derived-tau-in-acute-stroke-100525407","NCT06121336","PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke","PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke","PROMISE-BD-100","Inclusion Criteria:\n\n* clinical diagnosis of acute ischemic stroke\n* presentation within 9 hours of symptom onset\n* large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \\[segments M1-M4\\], ACA \\[segments A1-A3\\], basilar artery, or PCA \\[segments P1 to P3\\]) confirmed by CT or MRI angiography\n* at least 18 years of age\n* written informed consent\n\nExclusion Criteria:\n\n* CT or MRI showing intracranial hemorrhage upon admission\n* A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months\n* dementia\n* pre-stroke disability defined as a premorbid modified Rankin Scale score \\> 2",{"count":112,"type":22},100,"The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.",[28,115,116,117,118,119,120,121],"Stroke, Acute","Stroke, Ischemic","Cerebrovascular Disorders","Brain Diseases","Central Nervous System Diseases","Brain Ischemia","Nervous System Diseases",[28,123,124,125],"Brain injury","Biomarker","Pathophysiology",{"date":35,"type":38},{"date":128,"type":38},"2023-03-01",{"date":130,"type":22},"2027-03-31",{"name":132,"class":45},"Ludwig-Maximilians - University of Munich",{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":23,"phases":144,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":168},"100444268","phase-2-treatment-of-acute-ischemic-stroke-remedy2-trial-100444268","NCT05065216","Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","Phase 2\u002F3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)","ReMEDy2","Inclusion Criteria:\n\n1. Participant is between 18 and 90 years of age inclusive.\n2. Participant weight is 40 kg to 166 kg inclusive.\n3. Participant to be randomized and treatment initiated within 24 hours of last known normal\u002FAIS stroke onset.\n4. Participant has NIHSS ≥5 and ≤15 at approximately the time of randomization. This criterion also applies to participants who meet the following conditions:\n\n   * The participant initially presents with an NIHSS score below 5 but clinically worsens, including cases of progressing stroke \u002F stroke-in-evolution, resulting in a subsequent persistent NIHSS score of ≥5 and ≤15; and\n   * Participant meets all other inclusion and exclusion criteria, including repeat brain imaging to rule out hemorrhagic transformation.\n5. Participant had a pre-morbid mRS score of 0 to 1 (mRS score prior to AIS) as stated by participant or participant's representative.\n6. If participant has received fibrinolytic treatment for AIS within 4.5 hours of last know normal\u002FAIS stoke onset and at least 6 hours after completing fibrinolytic treatment, and the participant meets all of the following criteria:\n\n   * Participant's initial NIHSS score prior to fibrinolytics was ≤15; and\n   * At least six hours after fibrinolytics, the participant has NIHSS score of ≥5 and ≤15 with a persistent deficit; and\n   * The participant's NIHSS score showed less than a 4-point improvement, or worsened, after receiving fibrinolytics; and\n   * Participant meets all other inclusion and exclusion criteria including repeat brain imaging to rule out hemorrhagic transformation.\n7. Participant and\u002For legally authorized representative is able to provide informed consent.\n8. Participant is willing and able to comply with the study protocol, in the Investigator's judgment.\n\nExclusion Criteria:\n\n1. At screening, or with repeat imaging (see Inclusion 4 and 6), participant has imaging confirmed hemorrhage stroke.\n2. Participant has image findings with symptomatic large vessel occlusion at one or more of the following locations: Intracranial carotid I\u002FT\u002FL or M1 segment MCA, vertebral or basilar artery (BA).\n3. Participant has large core of established infarction defined as ASPECTS 0-5.\n4. Participant has or will receive MT for their current AIS.\n5. Participant has suspected or confirmed extracranial arterial dissection.\n6. Participant has imaging findings and\u002For symptoms consistent with a brain stem or cerebellar stroke. Posterior cerebral artery strokes without any associated brain stem or cerebellar involvement are allowable.\n7. Participant has any recorded SBP \\\u003C100 mmHg or MAP \\\u003C65 mmHg; MAP = DBP + \\[1\u002F3 (SBP - DBP)\\] (measured with noninvasive BP cuff type monitor) after stroke symptom onset and prior to randomization.\n8. Participant is currently prescribed angiotensin-converting enzyme inhibitor (ACEi) and is unable or unwilling to convert to another antihypertensive pharmacological treatment through Day 29 ±1 day (8 days after last treatment).\n9. Participant is currently prescribed an ACEi, and the last dose of the ACE inhibitor medication is reported to have been taken \\\u003C 24 hours before start of IV study drug infusion as stated by participant or participant's representative.\n10. Participant has a history of clinically significant allergic reactions such as angioedema or anaphylaxis requiring hospitalization.\n11. Participant has a diagnosis or suspected diagnosis of hereditary angioedema (HAE) or is taking or prescribed medications commonly used as prophylaxis\u002Ftreatment of HAE, such as C1-esterase inhibitors (Cinryze, Berinert, Ruconest, Haegarda), Danazol, kallikrein inhibitors (Ecallantide, Berotralstat, Lanadelumab), Bradykinin B2 Receptor Antagonists (Icatibant), or other medication designed to influence the kallikrein-kinin system.\n12. Life expectancy estimated at ≤1 year prior to enrollment.\n13. Participant has clinical evidence of an active infection at the time of enrollment requiring parenteral treatment or hospitalization to monitor or manage the infection.\n\n    NOTE: Treatment of uncomplicated infections with oral antibiotics would not be an exclusion (for example, the treatment of uncomplicated urinary tract infections or sinus infections with oral antibiotics would not be exclusionary).\n14. Participant has known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency).\n15. Participant is pregnant or nursing. NOTE: Participants who agree to stop nursing may be considered for inclusion at the discretion of the Investigator.\n16. Participants of child-bearing potential must agree to use medically acceptable contraceptive measures to prevent pregnancy. All participants of childbearing potential (defined as sexually mature participants who have had menses within the preceding 24 months and have not undergone permanent sterilization methods such as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) must have a negative serum pregnancy test performed locally at screening. Participants of childbearing potential must agree not to attempt to become pregnant or undergo in vitro fertilization. If participating in sexual activity that could lead to pregnancy, participants must use 2 reliable methods (1 per partner is acceptable) of contraception simultaneously while receiving protocol-specified medication and during the study follow-up period.\n\n    Participants participating in sexual activity must agree to use, or for their partner to use highly effective birth control methods (those with a failure rate of less than 1% per year when used consistently and correctly) until they have completed the study (after the Day 90 visit). Such methods include:\n    * Combined (estrogen and progesterone containing) hormonal oral, intravaginal, or transdermal contraception associated with the inhibition of ovulation\n    * Progesterone-only oral, injectable, or implantable hormonal contraception associated with the inhibition of ovulation\n    * Intrauterine device (IUD)\n    * Intrauterine hormone-releasing system (IUS)\n    * Bilateral tubal occlusion\n    * Vasectomized partner\n    * Sexual abstinence Participants who are not of reproductive potential (who have been postmenopausal for more than 24 consecutive months or have undergone hysterectomy, bilateral oophorectomy, bilateral salpingectomy, etc.) are not required to use contraception.\n\n    Participants are prohibited from sperm donation. NOTE: A negative serum pregnancy test will be documented during screening if a participant is of child-bearing potential.\n17. Participant is currently participating in or has participated in a study using an investigational device or drug or received an investigational drug or investigational use of a licensed drug within 30 days prior to screening.\n18. Participant does not have sufficient venous access for infusion of study treatment or blood sampling.\n19. Participant is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits.\n20. Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results.","90 Years",{"count":143,"type":22},728,[145,146],"PHASE2","PHASE3","This is a Phase 2\u002F3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.",[149,150,28],"Acute Stroke","Ischemic Stroke",[152,153,31,154,155,156,157,158,159],"acute","ischemic","AIS","tPA","LVO","MT","KLK1","Kallikreins",{"date":37,"type":38},{"date":162,"type":38},"2021-11-07",{"date":164,"type":22},"2026-12",{"name":166,"class":167},"DiaMedica Therapeutics Inc","INDUSTRY",86,{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":177,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":186,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":46},"100652941","ceeec-ii-a-12-week-physical-and-cognitive-enrichment-extension-study-in-older-stroke-survivors-with-multimorbidity-100652941","NCT07778771","CEEEC-II: A 12-Week Physical and Cognitive Enrichment Extension Study in Older Stroke Survivors With Multimorbidity","A 12-Week, Multicenter, Open-Label, 2×2 Factorial, Cluster-Assigned Extension Study of Upgraded Physical and AI-Enabled Large-Screen Cognitive Enrichment for Older Stroke Survivors With Multimorbidity in Kunshan, China","CEEEC-II","Inclusion Criteria:\n\n* Completed the endpoint assessment of the preceding CEEEC Phase I trial (NCT06975501) and remains under management at a participating community health service station in Kunshan.\n* Age 60 years or older.\n* Hospital-confirmed ischemic or hemorrhagic stroke in a stable stage, with no new or worsening neurological deficit within the previous 3 months.\n* Registered hypertension and\u002For type 2 diabetes mellitus; other comorbid conditions are permitted.\n* Willing and able to participate in the 12-week community-based extension program and complete baseline and endpoint assessments.\n* Able to travel to the community site independently or with a cane or walker; not dependent on a wheelchair for attendance.\n* Short Physical Performance Battery total score \\>=3, or able to maintain a supported side-by-side standing position for 10 seconds when the total score is \\\u003C3.\n* Able to communicate in Mandarin Chinese or the Kunshan dialect and able to recognize Arabic numerals.\n* Corrected vision sufficient to identify large characters at approximately 40 cm and at least one upper limb able to complete touchscreen selection.\n* Resides in the participating community and has no plan to move away during the study period.\n* Provides written informed consent specifically for CEEEC-II.\n\nExclusion Criteria:\n\n* Life-threatening disease or another condition associated with an expected survival of less than 6 months.\n* A new stroke, transient ischemic attack, acute coronary event, or hospitalization for decompensated heart failure within the previous 3 months.\n* Uncontrolled resting blood pressure (systolic \\>=180 mmHg or diastolic \\>=110 mmHg after repeated measurement) until clinically reassessed and controlled.\n* Extreme glycemic instability, including fasting blood glucose \\>16.7 mmol\u002FL or severe hypoglycemia requiring assistance within the previous month, until clinically reassessed.\n* An absolute contraindication to unsupervised community exercise or another medical condition judged by the study clinician to make participation unsafe.\n* Unable to walk to the community site even with a cane or walker, or dependent on a wheelchair for attendance.\n* A severe musculoskeletal, neurological, visual, hearing, cognitive, psychiatric, or communication impairment that prevents safe participation or valid completion of study procedures.\n* Unable to recognize Arabic numerals or unable to complete touchscreen selection with either upper limb.\n* Current participation in another structured physical, cognitive, or nutrition intervention study that may contaminate the assigned intervention.\n* Any other reason documented by the study clinician as making the individual unsuitable for participation.","60 Years",{"count":179,"type":22},365,[25],"CEEEC-II is a 12-week, community-based, prospective extension study conducted in 32 community health service stations in Kunshan, China. It will invite older stroke survivors with hypertension and\u002For type 2 diabetes who participated in the preceding CEEEC Phase I trial (NCT06975501) to provide new informed consent and complete Phase II eligibility and baseline assessments. Participants will remain in the physical enrichment, cognitive enrichment, combined enrichment, or usual-care arm assigned to their community cluster in Phase I; no new randomization will occur in CEEEC-II. The upgraded program includes eight physician-led Vitality Camp sessions and four volunteer-led reinforcement activities. The physical component integrates aerobic, resistance, balance, flexibility, Baduanjin, and nutrition education. The cognitive component integrates health education with age-adapted games delivered through an AI-enabled interactive large screen. The primary objective is to evaluate the marginal effect of the cognitive enrichment factor on intrinsic capacity at 12 weeks.",[28,183,184,185],"Hypertension","Type 2 Diabetes Mellitus (T2DM)","Multimorbidity",[187,188,189,190,191,192,193,194],"Intrinsic Capacity","Older Adults","Community Health Services","Environmental Enrichment","Cognitive Training","Physical Exercise","Multicomponent Intervention","Cluster-Assigned Extension Study","2026-08-18",{"date":37,"type":38},{"date":198,"type":22},"2026-08-31",{"date":200,"type":22},"2027-01-03",{"name":202,"class":45},"Duke Kunshan University",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":210,"sex":17,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":215,"conditions":216,"keywords":222,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":231,"locationsCount":4},"100652794","an-innovative-proprioceptive-instrument-for-upper-extremities-100652794","NCT07779928","An Innovative Proprioceptive Instrument for Upper Extremities","Development, Validation, and Clinical Application of an Innovative Proprioceptive Instrument for Upper Extremities: PropArm-PosiMoF (PropArm)","1. Healthy Young Adults:\n\n   Inclusion Criteria:\n   * (1) Age between 20 and 29 years,\n   * (2) Right-hand dominance, and\n   * (3) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Currently a student or faculty member of the Department of Occupational Therapy at National Cheng Kung University, or a staff member of the Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital,\n   * (2) History of surgery on the right upper limb,\n   * (3) Presence of neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, such as stroke or shoulder impingement syndrome, and\n   * (4) Uncorrected hearing problems, such as hearing loss.\n2. Healthy Adults:\n\n   Inclusion Criteria:\n   * (1) Age between 30 to 39, 40 to 49, or 50 to 59 years,\n   * (2) Right-hand dominance, and\n   * (3) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Currently a student or faculty member of the Department of Occupational Therapy at National Cheng Kung University, or a staff member of the Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital,\n   * (2) History of surgery on the right upper limb,\n   * (3) Presence of neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, such as stroke or shoulder impingement syndrome, and\n   * (4) Uncorrected hearing problems, such as hearing loss.\n3. Healthy Older Adults:\n\n   Inclusion Criteria:\n   * (1) Age between 60 to 69, 70 to 79, or 80 to 89 years,\n   * (2) Right-hand dominance, and\n   * (3) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n   * (2) Currently a student or faculty member of the Department of Occupational Therapy at National Cheng Kung University, or a staff member of the Department of Physical Medicine and Rehabilitation, National Cheng Kung University Hospital,\n   * (3) History of surgery on the right upper limb,\n   * (4) Presence of neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, such as stroke or shoulder impingement syndrome, and\n   * (5) Uncorrected hearing problems, such as hearing loss.\n4. Stroke:\n\n   Inclusion Criteria:\n   * (1) Age between 20 and 89 years,\n   * (2) Right-hemispheric hemorrhagic or ischemic stroke with lesions involving proprioceptive pathways or the primary somatosensory cortex, potentially resulting in difficulties with body position, movement, or force perception, or with fine tactile perception (e.g., localization, two-point discrimination, object recognition),\n   * (3) Right-hand dominance, and\n   * (4) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n   * (2) Upper limb still in acute pain stage,\n   * (3) Muscle tone severe enough to affect right upper limb movement (e.g., score ≥ 1+ on the Modified Ashworth Scale),\n   * (4) Uncorrected hearing problems, such as hearing loss.\n5. Shoulder Impingement Syndrome:\n\n   Inclusion Criteria:\n   * (1) Age between 20 and 89 years,\n   * (2) Diagnosis of shoulder impingement syndrome in the right upper limb,\n   * (3) Right-hand dominance, and\n   * (4) Ability to understand three consecutive verbal instructions.\n\n   Exclusion Criteria:\n   * (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n   * (2) Upper limb still in acute pain stage,\n   * (3) Uncorrected hearing problems, such as hearing loss.\n6. Diabetes (DM):\n\nInclusion Criteria:\n\n* (1) Age between 20 and 89 years,\n* (2) Diagnosis of diabetes mellitus by a specialist physician, based on one of the following:\n\n  1. Fasting plasma glucose (FPG) ≥ 126 mg\u002FdL or 7.0 mmol\u002FL;\n  2. Hemoglobin A1C (HbA1c) ≥ 6.5%;\n  3. Plasma glucose ≥ 200 mg\u002FdL or 11.1 mmol\u002FL at 2 hours during an oral glucose tolerance test (OGTT);\n  4. Presence of hyperglycemia symptoms (polyphagia, polyuria, polydipsia, and unexplained weight loss) with a random plasma glucose ≥ 200 mg\u002FdL.\n\nDiagnosis of diabetes is confirmed if any two of items (a-c) are met, or if any one of them remains positive on repeat testing; fulfillment of item (d) alone is also sufficient for diagnosis.\n\n* (3) Right-hand dominance, and\n* (4) Ability to understand three consecutive verbal instructions.\n\nExclusion Criteria:\n\n* (1) Score below the 5th percentile on the Color Trails Test-Chinese Version (CTT-C),\n* (2) History of surgery on the right upper limb,\n* (3) Presence of other neuromusculoskeletal disorders that may affect sensory or motor function of the right upper limb, and\n* (4) Current skin infection, and\n* (5) Uncorrected hearing problems, such as hearing loss.",true,"20 Years","89 Years",{"count":214,"type":22},280,"This study aimed to develop and validate an innovative proprioceptive assessment instrument for the upper extremities, the PropArm-PosiMoF (PropArm). This observational study was conducted in three stages. The first stage focused on the development and validation of PropArm, including test-retest reliability, concurrent validity, and convergent validity. The second stage established age norms and cut-off points in healthy adults. In the final stage, PropArm was applied to patients with proprioceptive impairments (stroke, shoulder impingement syndrome, and diabetes mellitus patients) to examine its diagnostic accuracy and clinical applicability.",[28,217,218,219,220,221],"Shoulder Impingement Syndrome","Diabetes (DM)","Healthy Young Adults","Healthy Adults","Healthy Older Adults",[223,224,225,226],"Proprioception","Upper Extremities","Instrument","Psychometric Properties",{"date":37,"type":38},{"date":229,"type":22},"2026-09-01",{"date":100,"type":22},{"name":232,"class":45},"National Cheng-Kung University Hospital",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":210,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":250,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":46},"100651071","the-basic-s-feasibility-study-for-vascular-risk-reduction-100651071","NCT07755631","The BASIC-S Feasibility Study for Vascular Risk Reduction","Piloting an Integrated Lifestyle Intervention for Vascular Risk Reduction: The BASIC-S Feasibility Study","BASIC-S","Inclusion Criteria:\n\n* Adults aged 18 years and older currently employed at or recently retired from the London Health Sciences Centre (LHSC) or Western University (with an operational focus on pre-retirees aged 50 years and older).\n* The primary applicant (not their partner, if applicable) must be within two years before or after their retirement date.\n* Spouse or cohabitating partner of an enrolled primary participant. Cohabitating partners may include a common-law partner, adult child, close friend, or roommate who lives with the primary participant and shares common health goals. Enrollment of partners is optional but strongly encouraged.\n* Capable of providing informed consent.\n* Has access to a mobile device capable of receiving Short Message Service (SMS) communications and viewing PDF documents.\n* Physically able to safely engage in light-to-moderate intensity physical activity.\n\nExclusion Criteria:\n\n* Medical conditions that preclude safe participation in physical activity (for instance, unstable angina, uncontrolled arrhythmia, severe heart failure) without physician clearance.\n* Active or unstable psychiatric illness, defined as hospitalization for psychiatric care within the preceding 6 months or modifications to antipsychotic or mood-stabilizing pharmacotherapy within the preceding 3 months. Participants with stable, medically managed psychiatric conditions remain eligible.\n* Severe cognitive impairment that compromises the ability to provide informed consent or independently use study-related technology.\n* Inability to read and understand English sufficiently to provide informed consent and complete study procedures.",{"count":242,"type":22},120,[25],"Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed the BASIC-S framework, targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.",[246,62,28,247,248,249],"Hypertension (HTN)","Dementia","Cardiovascular Risk Factor","Cognitive Decline",[251,252,253,254,255,66,256,257,258,259,260,261,262,263,264,265,266],"Lifestyle Intervention","Motivational Interviewing","Primary Prevention","Behavioral Medicine","Brain Health","Mental Health","Social Activity","Social Isolation","Physical Activity","Blood Pressure","Activity","Sleep","Interaction","Consumption","Support","Partnering",{"date":95,"type":38},{"date":269,"type":22},"2026-10-01",{"date":271,"type":22},"2027-10-01",{"name":273,"class":45},"Andrew Appleton",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":295},"100644396","neuroplastic-changes-due-to-an-exercise-intervention-that-aid-in-lower-limb-recovery-after-subcortical-stroke-100644396","NCT07663292","Neuroplastic Changes Due to an Exercise Intervention That Aid in Lower Limb Recovery After Subcortical Stroke","Inclusion Criteria:\n\n* chronic left or right subcortical stroke as defined by 6 months or more after a cardiovascular accident\n* lower extremity motor impairment due to stroke that causes a walking speed of less than 0.6 m\u002Fs during a 10m walk,\n* age 18-80 years old, and\n* Screen pass of the Stress test or Physician sign-off from the participant's health care team that they are cleared for a 12 week exercise intervention\n\nExclusion Criteria:\n\n* MRI contraindications, including implanted cardiac pacemakers and severe claustrophobia\n* any neurodegenerative condition other than stroke that may lead to lower extremity impairment\n* visual or auditory impairment that may hinder study procedures, and\n* any medical condition that would preclude from participation in a physical exercise intervention program.",{"count":281,"type":22},55,[25],"This study aims to develop imaging-based biomarkers to assess which chronic stroke participant with lower extremity disability may respond or resist high intensity interval training (HIIT).\n\nPrevious research suggests that physical exercise training is safe and could help improve the walking speed of non-ambulatory stroke survivors. However, inter-individual variability in response to exercise is extraordinarily high regardless of adherence, and predictors of response remain elusive.\n\nChronic stroke survivors with lower limb disability resulting in slow walking speeds will participate in 12 weeks of cycling exercise at Emory University under the guidance of a physical exercise instructor, 3 days a week, for 25-60 minutes. During some of the exercise sessions, the investigators will collect blood lactate with a finger prick. Brain scans with an MRI before and after the 12 weeks of exercise will be done; motor function tests that include walking, sitting down, standing up, and turning around will be collected. Participants' memory and thinking will be assessed, and participants will fill out questionnaires about their health before and after their stroke, and well as questions about their diet.\n\nThe participation will last between 14-16 weeks (up to 42 study visits).",[285,28],"Subcortical Lesions",[287],"High intensity interval training",{"date":35,"type":38},{"date":290,"type":22},"2026-09",{"date":292,"type":22},"2027-03",{"name":294,"class":45},"Emory University",2,{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":314,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":327,"locationsCount":46},"100583352","visual-restoration-using-focused-ultrasound-stimulation-and-immersive-virtual-reality-after-stroke-100583352","NCT06875206","Visual Restoration Using Focused Ultrasound Stimulation and Immersive Virtual Reality After Stroke","LIFU-IVR","Inclusion Criteria:\n\n* ≥ 18 years old of any gender and race\n* Clinical ischemic stroke or hemorrhagic (confirmed by CT or MRI) that occurred \\>= 6-24 months ago\n* Partial or complete homonymous hemianopsia on clinical exam\n\nExclusion Criteria:\n\n* Documented history of severe dementia with or without medication before stroke that affect subject's ability to participate in and be compliant to study protocol\n* Significant upper motor deficits and the subject cannot do IVR sessions at the baseline\n* History of seizures\n* Inability to get a new MRI\n* Presence of any ultrasonic stimulation risk factors: an electrically, magnetically, or mechanically activated metal or nonmetal implant including cardiac pacemaker, intracerebral vascular clips, or any other electrically sensitive support system; non-fixed metal in any part of the body; pregnancy (the effect of ultrasonic stimulation on the fetus is unknown); preexisting scalp lesion or wound or bone defect or hemicraniectomy.\n* Patients will be excluded if they have a previous diagnosis of hemianopsia, a new diagnosis of central retinal ischemic injury, or visual blindness or a history of any other ocular disease.\n* Concerns about the inability to complete study visits\u002Fprocedures by the PI.",{"count":304,"type":22},28,[25],"This research will explore if brain stimulation combined with virtual reality therapy improves visual impairment. The stimulation technique is called low-intensity focused ultrasound stimulation (LIFUS). The treatment uses ultrasound to stimulate vision specific parts of the brain. Before this therapy, the participants will get structural brain imaging. Functional brain imaging will be performed before and after the study's completion to measure brain activity response to therapy.\n\nThe purpose of this research study is to evaluate patients who have had a stroke between 6 and 24 months ago with a visual field impairment. The duration of active participation in the study is 1.5 months.",[28,308,309,310,311,312,313],"Visual Field Defect","Visual Field Defect Following Cerebrovascular Accident","Hemianopia","Quadrantanopia","Occipital Lobe Infarct","Visual Fields Hemianopsia",[315,31,316,317,318,319,320,321,322],"virtual reality","visual deficit","chronic stroke","ultrasound stimulation","neuromodulation","stroke recovery","visual field defect","funcational imaging",{"date":35,"type":38},{"date":229,"type":22},{"date":326,"type":22},"2028-10-31",{"name":328,"class":45},"Duke University",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":210,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":341,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":353},"100547528","high-definition-transcranial-electrical-stimulation-for-upper-extremity-rehabilitation-100547528","NCT06409143","High-definition Transcranial Electrical Stimulation for Upper Extremity Rehabilitation","Neural Mechanisms and Augmented Efficacy of High-definition Transcranial Electrical Stimulation on Upper-extremity Function in Patients With Subacute Stroke","Inclusion Criteria:\n\n\\- Sub-Project 1 (Healthy)\n\n1. Adults aged 18 and above.\n2. Confirmed right-handedness using the Edinburgh Handedness Inventory.\n\nSub-Project 1 (Post-stroke patients)\n\n1. Aged 18 and above.\n2. Diagnosed with stroke.\n3. Post-stroke for more than 6 months.\n4. Unilateral hemiparesis.\n\nSub-Project 2 (Subacute-stroke patients)\n\n1. Aged 18 and above.\n2. Diagnosed with stroke.\n3. Stroke occurred between 7 days to 6 months ago.\n4. Unilateral hemiparesis.\n5. Degree of recovery for proximal and distal movements of the affected upper limb is Brunnstrom stage III to V.\n6. No severe muscle spasticity in any segments of the affected upper limb (Modified Ashworth Scale ≤ 2).\n\nExclusion Criteria:\n\n\\- Sub-Project 1 (Healthy)\n\n1. History of neurological disorders (e.g., stroke, brain tumor, epilepsy), psychiatric disorders (e.g., substance abuse, major depression, schizophrenia, bipolar disorder), or musculoskeletal disorders of the upper limb.\n2. Contraindications to transcranial electrical stimulation, including history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure.\n3. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head.\n4. Participation in other invasive or non-invasive brain stimulation research studies.\n5. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.)\n6. History of alcohol or substance abuse.\n7. Damaged skin at the stimulation site, electrode contact, or device wearing site.\n8. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold.\n9. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.\n10. Affiliation with any research institution\u002Fexecution unit (e.g., students from NTU, Taipei Medical University).\n\nSub-Project 1 (Post-stroke patients)\n\n1. Contraindications to transcranial electrical stimulation include a history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure.\n2. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head.\n3. Severe neurological or psychiatric disorders other than stroke (such as major depression, schizophrenia, substance abuse, organic brain diseases, Parkinson's disease, brain tumors).\n4. Use of medications that may lower the seizure threshold.\n5. Undergoing other invasive or non-invasive brain stimulation therapies.\n6. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.)\n7. History of alcohol or substance abuse.\n8. Damaged skin at the stimulation site, electrode contact, or device wearing site.\n9. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold.\n10. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.\n\nSub-Project 2 (Subacute-stroke patients)\n\n1. Contraindications to transcranial electrical stimulation include a history of epilepsy, atrial fibrillation, presence of metal implants, cardiac pacemakers, convexity skull defects, or increased intracranial pressure.\n2. Skin allergies, contact dermatitis, abnormal pain, hypersensitivity to pain, wounds, or ulcers on the head.\n3. Severe neurological or psychiatric disorders other than stroke (such as major depression, schizophrenia, substance abuse, organic brain diseases, Parkinson's disease, brain tumors).\n4. Use of medications that may lower the seizure threshold.\n5. Other muscle and joint problems affecting upper limb function, such as joint contractures, rheumatoid arthritis, myositis ossificans.\n6. Severe cognitive impairment or receptive or global aphasia making it difficult to understand instructions.\n7. Hemineglect (including visual, auditory, or sensory neglect).\n8. Undergoing other invasive or non-invasive brain stimulation therapies.\n9. Pregnancy or lactating women. (If female, must be postmenopausal or surgically sterilized. Fertile women must have a negative pregnancy test result. Fertile female patients engaging in heterosexual intercourse, as well as fertile male patients with fertile female partners, must agree to use effective contraception during the trial period and for 4 months after the last dose of the investigational drug, such as oral contraceptives, dual barrier methods, intrauterine devices, or abstain from sexual intercourse during this period; non-fertile women are those who have undergone bilateral oophorectomy or are postmenopausal.)\n10. History of alcohol or substance abuse.\n11. Damaged skin at the stimulation site, electrode contact, or device wearing site.\n12. Long-term use of central nervous system affecting medications (such as antidepressants, sedatives) or other medications that may affect seizure threshold.\n13. Other conditions deemed unsuitable for transcranial electrical or magnetic stimulation by a physician.",{"count":337,"type":22},152,[25],"Upper limb hemiparesis is the most common sequelae in patients, severely impacting their independence and quality of life. Transcranial electrical stimulation (tCES) is a non-invasive and safe treatment, which uses a low direct current or alternating current to change the excitability of the cerebral cortex. It can induces long-term potentiation-like or long-term depression-like effects, thereby modulating the cortical excitability. In recent years, researchers have developed high-definition (HD) devices, which integrate high definition ring electrode configurations and incorporate direct current with theta burst stimulation waveforms. Diverging from traditional transcranial direct current stimulation (tDCS), which applies weak currents (0.5-2 mA) through two large sponge electrodes (25\\~35 cm\\^2) externally to the scalp for widespread non-specific cortical stimulation, HD-tES employs an array of small-area electrodes (1 cm\\^2) to control current distribution over localized cortical regions, thereby enhancing spatial accuracy. However, there is a lack of studies validating the optimal waveform for HD-tES, as well as clinical evidence in subacute stroke populations. The optimal unilateral versus bilateral stimulation modes and their neurological mechanisms for stroke rehabilitation also remain uncertain.",[28],[28,342,343,344,345],"High-Definition Transcranial Electrical Stimulation","Upper-limb rehabilitation","Transcranial electrical stimulation","Neuroplasticity",{"date":35,"type":38},{"date":348,"type":38},"2024-08-15",{"date":350,"type":22},"2027-11-30",{"name":352,"class":45},"National Taiwan University Hospital",3,{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":369,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":380},"100494880","carotid-implants-for-prevention-of-stroke-recurrence-from-large-vessel-occlusion-in-atrial-fibrillation-patients-treated-with-oral-anticoagulation-100494880","NCT05723926","Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation","INTERCEPT","Inclusion Criteria:\n\n1. Documented history of clinical AF\n2. History of ischemic (i.e. non-hemorrhagic) stroke including symptoms of stroke resolving within 24 hours with positive neuro-imaging, meeting one of the following criteria:\n\n   Group 1: Patient was on OAC at time of index stroke, with index stroke occurring \\\u003C 6 week from enrollment Group 2: Patient was not on OAC at time of stroke, with index stroke occurring \\\u003C 6 weeks from enrollment Group 3: Patient was on OAC at time of index stroke, with index stroke occurring 6 to 52 weeks from enrollment\n3. Planned use of a Vitamin K antagonist (VKA) or a direct oral anticoagulant (DOAC) for the duration of the trial\n4. Patient able to tolerate single antiplatelet therapy in addition to oral anticoagulation for 6 months, in the opinion of the investigator\n5. Bilateral ultrasound or angiogram demonstrating all of the following:\n\n   1. Inner common carotid artery diameter range: ≥5.3 mm and ≤8.8 mm\n   2. Accessibility: up to 40 mm from skin to common carotid artery center\n   3. Implantation segment free of any atherosclerotic disease\n   4. Absence of carotid dissection or pre-existing stent(s) in common carotid artery\n   5. Absence of ≥50% stenosis of the internal carotid arteries as seen on ultrasound or angiography (CTA, MRA or DSA)\n\n   i. For ultrasound, calculate the percentage of carotid stenosis using the Society of Radiologists in Ultrasound Consensus Criteria for Carotid Stenosis, where ≥50% stenosis is defined by internal carotid artery peak systolic velocity of ≥125 cm\u002Fsec, internal\u002Fcommon carotid peak systolic velocity ratio of 2 or more and end diastolic velocity of ≥40 cm\u002Fsec, or evidence of near occlusion.\n\n   ii. For angiography, calculate the percentage of carotid stenosis using the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria (\\[D - N\\]\u002FD x 100, where N is the luminal diameter at the site of maximal narrowing and D is the diameter of normal distal internal carotid artery beyond the bulb where the artery walls are parallel.\n6. Provision of informed consent\n\nExclusion Criteria:\n\n1. Contraindication to oral anticoagulation (e.g. history of intracranial hemorrhage, known hereditary or acquired coagulation disorders, or recurrent major bleeding)\n2. Contraindication to additional single antiplatelet therapy for 6 months from randomization\n3. Previously documented 50% or greater stenosis, or high-risk plaque in the opinion of the investigator, of the common carotid, internal carotid, subclavian, vertebral, or intracranial arteries that has not been treated with a revascularization procedure (i.e. stent or angioplasty)\n4. Visualized active (acute\u002Fsubacute) cervical or intracranial arterial thrombus (i.e. free-floating) on computed tomography (CT), magnetic resonance (MR), or digital subtraction (DS) angiography that is at risk of causing additional stroke\u002Fbrain injury\n5. Previously documented aneurysm of the internal carotid artery or its branches (i.e. ophthalmic, posterior communicating, anterior choroidal, anterior cerebral and middle cerebral arteries) that is 6 mm or greater in diameter.\n6. Prior surgery or radiation of the neck at the implantation segment\n7. Pre-existing percutaneous left atrial appendage occlusion device that was implanted after most recent ischemic stroke\n8. Planned left atrial appendage occlusion procedure\n9. Female who is pregnant or non-postmenopausal female who is not willing to use an effective method of birth control during duration of the trial\n10. Overt systemic infection\n11. Known sensitivity to nickel or titanium metals, or their alloys\n12. Active participation in another investigational drug or device treatment trial\n13. Any other condition that in the opinion of the investigator may adversely affect the safety of the patient or would limit the patient's ability to complete the trial",{"count":362,"type":22},2000,[25],"Patients with atrial fibrillation (AF) who have had a prior stroke are at very high risk of recurrent ischemic stroke. About 40% of these strokes are due to large emboli which result in large cerebral vessel occlusion (LVO). This randomized control trial aims to address this unmet need by testing whether use of bilateral carotid filter implants in addition to OAC will reduce the risk of stroke in AF patients with recent (e.g. within 12 months) ischemic stroke vs. only OAC.",[366,367,28,368],"Atrial Fibrillation","Oral Anticoagulation","Implant",[370,371,372,156],"Filter","Ischemic stroke","NOAC",{"date":95,"type":38},{"date":375,"type":38},"2026-01-09",{"date":377,"type":22},"2030-10-20",{"name":379,"class":167},"Javelin Medical",21,{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":388,"maxAge":389,"enrollmentInfo":390,"targetDuration":4,"studyType":23,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":399,"leadSponsor":401,"locationsCount":46},"100478220","phase-2-a-digital-intervention-for-post-stroke-depression-and-executive-dysfunction-100478220","NCT05507138","A Digital Intervention for Post-Stroke Depression and Executive Dysfunction","Efficacy and Target Engagement of a Digital Intervention to Improve Depression and Executive Dysfunction After Stroke","Inclusion Criteria:\n\n* first-time stroke that occurred 6 months or more prior to study initiation\n* executive dysfunction as defined by a score of less than 1 standard deviation below age-adjusted normative score on at least one test of executive function in the screening assessment\n* diagnosis of Major Depressive Episode assessed by the Structured Clinical Interview for the DSM-5 (SCID).\n* at least moderate depressive symptoms as defined by Montgomery Asberg Depression Rating Scale ≥ 18\n* motor function sufficient to operate an iPad and use a pen, based on self-report and observation\n* if treated with an antidepressant medication, must be on a stable dose for a minimum of 8 weeks at the time of study enrollment.\n* able to adhere to all testing and study requirements and willingness to participate in the full study duration\n\nExclusion Criteria:\n\n* receptive aphasia as determined by a score of 2 or 3 on the NIH Stroke Scale \\[NIHSS\\] item 9 (\"Best Language\")\n* dysarthria that makes speech unintelligible (score of 2 on NIHSS item #10)\n* severe visual impairment or hemispatial neglect (score of 3 on NIHSS item #3 or score of 2 on NIHSS item #11)\n* patient already enrolled in ongoing concurrent cognitive rehabilitation (note that if a subject is already enrolled in psychotherapy, this will not be grounds for exclusion)\n* non-fluency in English\n* presence of or history of significant neurologic or neurodegenerative disorder other than stroke\n* presence of dementia based on dependence in basic ADLs due to cognitive deficits\n* history of psychosis or mania (evaluated using the SCID).\n* active suicide ideation (assessed via the Columbia Suicide Severity Rating Scale)\n* severe executive dysfunction (based on clinical judgment during screening evaluation) precluding use of the iPad\n* severe depression-even in the absence of active suicidal ideation-based on the screening evaluation and clinical judgment of the PI, which warrants a higher level of care and\u002For immediate referral to psychiatric services.\n* pregnancy\n* any other clinical or medical reason in the PI's initial screening evaluation that suggests the study is not appropriate for the participant.","50 Years","79 Years",{"count":391,"type":22},70,[145],"Individuals with stroke commonly experience both depression and cognitive difficulties. The goal of this study is to evaluate the efficacy of a treatment that combines a digital therapeutic (an iPad-based cognitive training program) with learning cognitive strategies. The hypotheses are that this treatment will improve cognitive skills, depression symptoms, daily function, and brain connectivity. In the short-term, the findings will inform the efficacy of the intervention and in the long-term, may support the use of the intervention to improve co-occurring cognitive and mood difficulties after stroke.",[395,396,28],"Executive Dysfunction","Depression",{"date":35,"type":38},{"date":128,"type":38},{"date":400,"type":22},"2027-09-30",{"name":402,"class":45},"Weill Medical College of Cornell University",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":412,"conditions":413,"keywords":414,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":422},"100465283","validation-of-early-prognostic-data-for-recovery-outcome-after-stroke-for-future-higher-yield-trials-100465283","NCT05338697","Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials","VERIFY","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Unilateral symptomatic stroke due to ischemia. (Note: Bilateral acute stroke is permitted if the stroke that is contralateral to the index stroke is asymptomatic).\n3. Motor deficits in the acutely affected UE, defined as a Shoulder Abduction and Finger Extension (SAFE) score ≤ 8 out of 10 points20,61 (i.e., excluding full or nearly full motor strength in both shoulder abduction and finger extension) within 48 to 96 hours of stroke onset (or time last known well).\n\n   a. Please note that, if significant imbalance is observed in SAFE score or MEP+ rates, the enrollment threshold for SAFE score may be updated with a formal study memo.\n4. Provision of signed and dated informed consent form within 24 to 96 hours of stroke onset, (or time last known well). Note: Participant is considered \"enrolled\" upon starting TMS (at least one stimulation is delivered) or starting study-specific MRI pulse sequence (at least one MRI beep occurs)\n5. Stated willingness to comply with all study procedures and availability for the duration of the study, including Day 90 visit which must occur in-person.\n6. Fluent in study approved languages (i.e., English or Spanish)\n\nExclusion Criteria:\n\n1. UE injury or conditions on paretic side that limited use prior to the stroke\n2. Legally blind\n3. Dense sensory loss on paretic side indicated by a score of 2 on NIHSS sensory item\n4. Unable to abduct the shoulder or extend the fingers of the non-paretic UE on verbal command\n5. Isolated cerebellar stroke\n6. Symptomatic stroke in any location within 30 days prior to index stroke.\n7. Co-enrollment in a trial of an intervention targeting the incident stroke (acute treatment or rehabilitation\u002Frecovery intervention) after baseline assessments for VERIFY are initiated\n8. Known or expected inability to maintain follow-up with study procedures through 90 days\n9. Cognitive or communication impairment precluding informed consent by the participant.\n10. Major medical, neurological, or psychiatric condition that would substantially affect functional status\n11. Non-cerebrovascular diagnosis associated with unlikely survival at 90 days\n12. Pregnancy\n13. Contraindication to noncontrast MRI (certain metallic implants, metallic foreign bodies or severe claustrophobia)\n14. Contraindication to TMS\n\n    1. Implanted electronic cardiac devices (e.g., Automatic Implantable Cardioverter-Defibrillator \\[AICD\\] or pacemaker)\n    2. Any electronic devices in the body at or above the level of the seventh cervical vertebra (such as cochlear implant, cortical stimulator, deep brain stimulator, vagus nerve stimulator, cervical spine epidural stimulator, or ventriculoperitoneal shunt)\n    3. Ferromagnetic intracranial metallic implant\n    4. Skull defect related to current stroke\n    5. Seizure after onset of current stroke\n    6. Seizure within the last 12 months while taking anti-epileptic medications\n    7. Previous serious adverse reaction to TMS\n15. Anticipated inability to perform study procedures within 168 hours of symptom onset\n\n    1. Unable to perform behavioral assessments within 48-120 hours of symptom onset (or time last known well).\n    2. Unable to receive TMS within 72-168 hours or get MRI within 48-168 hours of symptom onset (or time last known well).",{"count":411,"type":22},657,"VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.",[28,115,116],[408],{"date":35,"type":38},{"date":417,"type":38},"2022-06-18",{"date":419,"type":22},"2027-10",{"name":421,"class":45},"Yale University",45,{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":23,"phases":432,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":46},"100647154","emg-directed-virtual-reality-training-for-motor-stroke-rehabilitation-100647154","NCT07705256","EMG-Directed Virtual-Reality Training for Motor Stroke Rehabilitation","Pilot Study of EMG-Directed Virtual-Reality Experience Training for Motor Stroke Rehabilitation","Inclusion Criteria:\n\n* Aged 18 or over\n* Cognitive status that would permit for use \u002Fsupported use of intervention device and engagement in protocol related trainings\u002Fassessment. To be indicated by treating clinician at point of screening, formal capacity assessment to be conducted as appropriate. Refer to easy read patient information sheet (PIS) and training materials to support all patients presenting with specific cognitive and\u002For communication needs.\n* (We do not wish to exclude patients with cognitive impairment as this would limit the heterogeneity of our sample and generalizability of our findings, given the prevalence of cognitive impairment in stroke patients.)\n* Stroke diagnosis (can be first or subsequent stroke, unilateral haemorrhagic or ischemic) 2 weeks max post stroke at time of recruitment.\n* Can communicate in English, that is, sufficient for completion of intervention and outcome measures. A speech and language therapist (SLT) will be consulted if necessary to ensure all reasonable accommodations are made to support participation.\n* UL motor deficit post stroke (bilateral\u002Funilateral) (according to National Institutes of Health Stroke Score (NIHSS) item 5), distal UL power \\\u003C1 \u002F5 on the Oxford Rating Scale (Medical Research Council Manual Muscle Testing scale).\n\nExclusion Criteria:\n\n* Patients already enrolled an interventional neuro rehabilitation trial.\n* Patients enrolled in clinical trials that contraindicate co-enrolment.\n* Patients presenting with unstable medical conditions\u002Fmedical contraindications as determined by treating medical consultant (these patients may be approached at a later date should their condition improve).\n* Those registered blind\u002Fwith uncompensated\u002Funcorrected visual deficits, including severe neglect that prevents them from being able to focus on visually provided feedback.\n* Behavioural\u002Faffective dysfunction which could influence the ability of the person to engage with the research protocol and\u002For pose risk to the participating researchers (in circumstances such as follow-up community visits).\n* Other concomitant neurological disorders affecting upper extremity motor function (Multiple Sclerosis, Spinal Cord Injury, Brachial Plexus or Radial Nerve Injury).\n* Unremitting arm, wrist or hand pain at rest (Numeric Pain Rating Scale \\> 4). Consumption of caffeine 2 hours prior to assessment (assessment will be postponed to a later time).\n* Pre-existing UL impairment with known and significant disruption to range of motion, motor or functional performance (fracture, arthritic changes, other known musculoskeletal problems). Or pre-modified Rankin Score \\> 2.\n* Skin condition apparent on the ventral UE such that might place participant at risk of irritation in the context of repeated physical contact (such as that associated with the intervention).\n* Subsequent MRI that fails to confirm stroke\n* Chronic stroke patients whose stroke occurred in excess of 2.5 years ago\n* Patients whose cognitive impairment prevents them from following instructions",{"count":431,"type":22},24,[25],"This study is testing whether rehabilitation using muscle activity signals can help improve arm and hand movement in people after stroke or spinal cord injury.\n\nIn the main study, participants will use a virtual-reality feedback system that is controlled by surface electromyography (EMG). Surface EMG uses sensors placed on the skin to detect muscle activity. The feedback will help participants practise upper limb movements during rehabilitation.\n\nA related sub-study will run alongside the main study. In this sub-study, functional electrical stimulation will also be used to help activate muscles during training.\n\nThe study will assess whether these rehabilitation approaches improve upper limb function. It will also explore whether changes in biological or movement-related markers are linked with recovery.",[28,435],"Spinal Cord Injuries (Complete and Incomplete)",[437,438,439,33,440,441],"Stroke rehabilitation","upper limb rehabilitation","EMG biofeedback","neurorehabilitation","spinal cord injury rehabilitation","2026-08-17",{"date":195,"type":38},{"date":445,"type":22},"2026-07-27",{"date":447,"type":22},"2027-11-27",{"name":449,"class":45},"Imperial College London",{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":46},"100633234","impact-of-a-nursing-educational-consultation-on-the-patients-adherence-to-their-post-stroke-care-plan-100633234","NCT07524036","Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan.","Impact of a Nursing Consultation at the End of Hospitalization on Adherence to the Post-stroke Care Plan for Patients Admitted to the Vascular Neurology Unit","ICEIPAVC","Inclusion Criteria:\n\n* Patients admitted to the Neurovascular Unit (UNV) of CHCB for ischemic stroke and\u002For hemorrhagic stroke confirmed by brain imaging and\u002For TIA with an ABCD2 score \\>5,\n* Patients whose discharge orientation is a return home\n* Age ≥ 18 years\n* NIHSS \\\u003C 15\n* Montreal Cognitive Assessment (MoCa) \\> 21\u002F30\n* Free and informed consent signed by the patient.\n* Person affiliated with or a beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patients admitted for mechanical thrombectomy, outside the Basque Coast Hospital (CHCB)\n* Rankin score estimated at discharge ≥ 4\n* Patients requiring assistance from a third party at home for the management of their medication or with stroke follow-up at Prado\n* Patients placed under protection measures",{"count":459,"type":22},300,[25],"This prospective, single-center, randomized study will evaluate the impact of implementing an educational nursing consultation at the end of hospitalisation for stroke patients returning home on overall adherence to stroke-related medication during the 4-month follow-up visit.",[28,463],"Patient Education",[31,465,466],"patient education","post stroke consultation",{"date":195,"type":38},{"date":469,"type":38},"2026-06-11",{"date":471,"type":22},"2028-06-11",{"name":473,"class":45},"University Hospital, Bordeaux",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":23,"phases":484,"briefSummary":485,"conditions":486,"keywords":489,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":494,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":46},"100629226","robot-assisted-gait-training-vs-visual-feedback-balance-training-in-stroke-100629226","NCT07471919","Robot-Assisted Gait Training vs Visual Feedback Balance Training in Stroke","Comparison of Robot-Assisted Gait Training and Visual Feedback Balance Training on Balance and Gait Outcomes in Patients With Stroke","Inclusion Criteria:\n\n* Age 21-85 years\n* Diagnosis of ischemic or hemorrhagic stroke confirmed by clinical and radiological findings\n* Functional Ambulation Category (FAC) ≥ 3\n* Modified Ashworth Scale ≤ 2 (lower extremity)\n* Ability to understand and follow simple verbal instructions\n* Mini-Mental State Examination (MMSE) score ≥ 23\n\nExclusion Criteria:\n\n* Unstable cardiopulmonary conditions\n* Severe musculoskeletal disorders affecting standing or walking\n* Severe aphasia preventing participation in assessments\n* Severe visual impairment interfering with balance testing","85 Years",{"count":483,"type":22},50,[25],"Stroke frequently leads to balance impairment and gait dysfunction, increasing fall risk and limiting functional independence. Technology-assisted rehabilitation approaches such as robot-assisted gait training and visual feedback balance training have been shown to improve balance and mobility in stroke patients.\n\nThis randomized, assessor-blinded clinical trial aims to compare the effects of robot-assisted gait training and visual feedback balance training on balance and gait outcomes in patients with subacute and chronic stroke. Both interventions are part of routine clinical rehabilitation practice. Participants will be evaluated at baseline and after 4 weeks of intervention using clinical balance, gait, and functional assessments.",[28,487,488],"Gait Impairment","Balance Impairment",[437,490,491,492,493],"Robot-assisted gait training","Visual feedback balance training","Balance impairment","Gait impairment",{"date":95,"type":38},{"date":496,"type":38},"2026-03-15",{"date":498,"type":22},"2026-08-15",{"name":500,"class":45},"Abant Izzet Baysal University",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":511,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":524},"100568530","telerehabilitation-in-the-home-after-stroke-100568530","NCT06682429","Telerehabilitation In The Home After Stroke","Telerehabilitation In The Home After Stroke: A Randomized, Controlled, Assessor-Blind Clinical Trial","TR-2","Inclusion Criteria:\n\n1. Age 18-80 years at the time of randomization\n2. The index stroke was radiologically verified, due to ischemia or intracerebral hemorrhage (ICH), and had time of onset 120±30 days prior to randomization\n3. The stroke caused upper extremity deficits as defined by Action Research Arm Test score 18-44 (out of 57) at Baseline Visit 1\n4. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit 1\n5. Able to successfully perform all 3 rehabilitation exercise test examples (simple commands) at Baseline Visit 1\n6. Informed consent and behavioral contract signed by the subject (i.e., no surrogate consent)\n\nExclusion Criteria:\n\n1. A major, active, coexistent neurological, psychiatric, or medical disease that reduces the likelihood that a subject will be able to comply with all study procedures\n2. Unable or unwilling to perform study procedures\u002Ftherapy, or expectation of noncompliance with study procedures\u002Ftherapy, or expectation that subject cannot participate in all study visits\n3. A diagnosis (apart from the index stroke) that substantially affects paretic arm function\n4. Severe depression, defined as Geriatric Depression Scale Score \\>10\u002F15 at Baseline Visit 1\n5. Significant cognitive impairment, defined as Montreal Cognitive Assessment score \\\u003C22 \\[a lower score is permitted if due to aphasia and allowed by the site PI\\]\n6. Deficits in communication that interfere with reasonable study participation\n7. Severe UE spasticity, defined as presence of contracture or modified Ashworth Scale score=4 in either biceps or pectoralis\n8. Modified Rankin Scale score was \\>2 prior to the index stroke\n9. A new symptomatic stroke has occurred since the index stroke, or a separate stroke occurred within 30 days prior to the index stroke\n10. Lacking visual acuity, with or without corrective lens, of 20\u002F50 or better in at least one eye\n11. Life expectancy \\\u003C 9 months\n12. Pregnant; women of child-bearing potential must have a negative pregnancy test\n13. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected by the 8-Month Visit\n14. Concurrent enrollment in another therapy-based investigational study where the duration of the investigational therapy's activity is likely to occur during the subject's participation in the study\n15. Subject lacks sufficient English or Spanish to comply with study procedures and TR instructions\n16. Expectation that subject will not have a single domicile address during the 6 weeks of therapy that is within 1.5-hr drive of the central study site \\[this can be waived at the discretion of the site PI\\]\n17. Contraindication to MRI\n18. On isolation precautions, e.g., due to active COVID-19",{"count":510,"type":22},202,[25],"The purpose of this research study is to evaluate whether telerehabilitation targeting arm movement, when added to usual care, improves arm function and reduces global disability after stroke, compared to usual care alone.\n\nPatients with arm weakness due to stroke that happened in the past 90-150 days will be randomized into one of two groups: \\[1\\] TR and usual care; \\[2\\] usual care only (no TR), but people in the usual care group will be offered TR once the study is done. TR consists of 70 minutes\u002Fday of activities targeting arm function, 6 days a week for 6 weeks.",[28],[31,515,516],"rehabilitation","telehealth",{"date":95,"type":38},{"date":519,"type":38},"2025-08-22",{"date":521,"type":22},"2030-06",{"name":523,"class":45},"University of California, Los Angeles",27,{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":542,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":549,"leadSponsor":550,"locationsCount":46},"100633113","enhancing-attention-and-processing-speed-through-home-based-music-rehabilitation-program-after-stroke-in-malaysia-100633113","NCT07522463","Enhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia","Enhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia: A Feasibility Random Controlled Study","HMRPAS","Inclusion criteria:\n\n1. Age \\\u003C 75 years\n2. First-episode stroke within the last 12 months\n3. Montreal Cognitive Assessment (MoCA) of 15- 25, with impairment defined as failure to achieve the prespecified minimum score on the attention-related MoCA items.\n4. Sufficient cognitive ability to follow multi-step instructions\n5. Functional use of at least one upper limb to perform musical\u002Frhythmic movements\n6. Medically stable with the ability to maintain an upright sitting position with good balance\n\nExclusion criteria:\n\n1. Uncontrolled psychiatric or behavioural disorders that may interfere with participation\n2. Uncontrolled seizures or epilepsy\n3. Significant aphasia or hemispatial neglect\n4. Severe visual or visual field deficits","75 Years",{"count":535,"type":22},44,[25],"Stroke often leads to significant cognitive impairment, impacting quality of life. While existing rehabilitation options exist, there's a need for innovative, accessible, and patient-centered solutions. Research suggests music can engage multiple brain networks associated with sensory and motor processes, cognition, and affective regulation, potentially enhancing cognitive functions like attention and processing speed as well. Home-based interventions have also demonstrated positive impacts on rehabilitation adherence and outcomes. Building on this foundation, this study proposes to develop and pilot test a home-based musical rehabilitation program to improve attention and processing speed in Malaysian stroke survivors.",[28,539,540,541],"Attention","Rehabilitation Program","Music Intervention",[539,543,544,28,545],"Processing Speed","Home-based Music Rehabilitation Program","Malaysia","2026-08-16",{"date":95,"type":38},{"date":229,"type":22},{"date":100,"type":22},{"name":551,"class":45},"University of Malaya",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":210,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":559,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":46},"100386468","the-beneficial-effects-of-naps-on-motor-learning-100386468","NCT04312126","The Beneficial Effects of Naps on Motor Learning","Mechanisms Underlying the Beneficial Effects of Naps on Motor Learning","* HEALTHY VOLUNTEERS:\n\nINCLUSION CRITERIA:\n\n* Age 18-35 (Arm 1) or 50-80 (Arms 2).\n* English speaking.\n* Clear right-hand dominance (\\>74 on Edinburgh Handedness Inventory).\n* Normal neurological examination as determined by the screening clinician.\n\nEXCLUSION CRITERIA:\n\n* HCPS affiliated NIH staff (i.e. - staff from our section).\n* Current pregnancy.\n* Contraindications for MRI or MEG.\n* Use of sleep medications within 24 hours of Experimental Session participation.\n* Severe or progressive neurological, psychological or medical condition as determined by the screening clinician.\n\nSTROKE PATIENTS:\n\nINCLUSION CRITERIA:\n\n* Age 18 or older\n* Willing and able to provide consent\n* Experienced a stroke 6 months ago or more that affected at least one of the upper extremities at time of stroke diagnosis\n* Ability to perform the study task as assessed during physical examination\n* English-speaking\n\nEXCLUSION CRITERIA:\n\n* HCPS-affiliated NIH staff (i.e. - staff from our section).\n* Current pregnancy\n* History of large stroke lesions in brainstem or cerebellum as determined by screening clinician\n* Severe or progressive neurological disorder other than stroke (e.g., Parkinson s disease or multiple sclerosis) as determined by the screening clinician\n* Uncontrolled heart, lung, kidney, gastrointestinal, metabolic, psychiatric, sleep, or endocrine disorders as determined by the screening clinician\n* Contraindications for MRI or MEG.",{"count":560,"type":22},199,"Background:\n\nMemory consolidation is the process by which memories become stable, long-term representations in the brain. Consolidation of a motor skill is dependent upon sleep. Some research shows that daytime naps improve people s motor performance and memory retention. Researchers want to find out how daytime naps may contribute to learning and support consolidation of motor skill memories.\n\nObjective:\n\nTo learn the role of memory replay during wakeful rest and sleep (naps) in retaining a newly learned skill.\n\nEligibility:\n\nEnglish-speaking adults ages 18 and older with chronic stroke, or healthy, right-handed, English-speaking adults ages 18-35 and 50-80\n\nDesign:\n\nParticipants will be screened with:\n\n* medical history\n* neurological history\n* medicine review\n* medical exam\n* neurological exam.\n\nParticipants will have a magnetic resonance imaging (MRI) scan of the brain. For this, they will lie down in a scanner. The scanner makes loud noises, so they will wear earplugs. They will fill out an MRI screening form before each MRI.\n\nParticipants will also have magnetoencephalography (MEG). MEG maps brain activity. It does this by recording the magnetic fields produced by naturally occurring electrical currents in the brain. For MEG, participants will lie down in the MEG room. Their eye movements may be recorded by a video camera.\n\nParticipants will have behavior testing. They will practice typing random keys. Then they will repeatedly type a custom sequence that they see on a computer screen. Then they will take a 2-hour nap. Then they will type the same sequence again.\n\nParticipants will have no more than 4 visits at the NIH over 3 months. Visits will last 2-4 hours each.",[28],[564,262,565,566],"Motor Skill","Neural Replay","Natural History",{"date":195,"type":38},{"date":569,"type":38},"2021-03-04",{"date":571,"type":22},"2027-08-01",{"name":77,"class":78},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":580,"targetDuration":582,"studyType":58,"phases":4,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":46},"100652411","digital-health-literacy-and-social-participation-in-individuals-with-hemiplegia-100652411","NCT07773038","Digital Health Literacy and Social Participation in Individuals With Hemiplegia","The Association Between Digital Health Literacy and Social Participation in Individuals With Hemiplegia: A Cross-Sectional Study","Inclusion Criteria:\n\nAge 18 years or older Diagnosis of hemiplegia following stroke History of stroke at least 6 months before enrollment Ability to communicate sufficiently to complete the study assessments Mini-Mental State Examination score of 24 or higher Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\nSevere aphasia preventing completion of the assessments Advanced cognitive impairment Severe psychiatric disorder that may interfere with participation or completion of the assessments Visual or hearing impairment that prevents completion of the questionnaires",{"count":581,"type":22},250,"1 Day","This cross-sectional observational study aims to investigate the association between digital health literacy and social participation in individuals with hemiplegia after stroke. A total of 250 adults with a history of stroke at least 6 months previously will be included. Digital health literacy will be assessed using the eHealth Literacy Scale (eHEALS), and social participation will be assessed using the Reintegration to Normal Living Index (RNLI). The secondary aim is to examine the associations of digital health literacy with anxiety and depression, functional independence, and fatigue.",[28,585],"Hemiplegia",[587,588,589,585,590,591,592],"Digital Health Literacy","Social Participation","Stroke Rehabilitation","eHealth Literacy","Community Reintegration","Functional Independence","2026-08-14",{"date":95,"type":38},{"date":596,"type":22},"2026-08-28",{"date":598,"type":22},"2027-02-28",{"name":600,"class":45},"Afyonkarahisar Health Sciences University",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":4,"eligibilityCriteria":607,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":46},"100652002","electrical-stimulation-exercise-for-individuals-with-lower-limb-paralysis-100652002","NCT07768761","Electrical Stimulation Exercise for Individuals With Lower Limb Paralysis","Efficacy of Electrical Stimulation Exercise Training for Those With Lower Limb Paralysis","Inclusion Criteria:\n\n* Lower limb paralysis due to SCI or other neurological disorder\n* Greater than 18 years of age\n* Innervated and excitable lower extremity muscles\n\nExclusion Criteria:\n\n* Females that are pregnant\n* Ventilator dependent\n* Current pressure injuries that would be exacerbated by exercise\n* History of spontaneous fractures\n* Cardiovascular or pulmonary disease that would limit the ability to exercise\n* Uncontrolled diabetes or hypertension\n* Large body frame that would prevent participant from comfortably fitting the exercise equipment\n* Any other medical or psychological condition that would be a contraindication to participating in an exercise program",{"count":87,"type":22},[25],"The purpose of this research study is to evaluate the effectiveness of an exercise training intervention (24-36 sessions) to improve muscle strength and endurance in the lower limbs of individuals with paralysis. Specifically, surface electrical stimulation or previously implanted stimulator will be used to stimulate the muscles during various forms of exercise training with the primary focus on improving overall endurance and maximal power output. For this study, peripheral stimulating electrodes will send electrical signals to the muscles enabling the production of coordinated movements for exercise such as cycling or rowing.",[612,28,613,614],"Spinal Cord Injury\u002FDisorder","Multiple Sclerosis","Traumatic Brain Injury",{"date":442,"type":38},{"date":617,"type":38},"2018-01-19",{"date":619,"type":22},"2031-01-19",{"name":621,"class":622},"Louis Stokes VA Medical Center","FED",{"id":624,"slug":625,"hasResults":12,"nctId":626,"briefTitle":627,"officialTitle":627,"acronym":628,"eligibilityCriteria":629,"healthyVolunteers":210,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":630,"targetDuration":4,"studyType":23,"phases":632,"briefSummary":634,"conditions":635,"keywords":636,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":593,"lastUpdatePostDateStruct":643,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":46},"100567321","early-phase-1-effect-of-neural-constraints-on-movement-in-stroke-100567321","NCT06666673","Effect of Neural Constraints on Movement in Stroke","ENCMS","Inclusion Criteria:\n\n* History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment\n* Age between 18-80\n* Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50\u002F66)\n* Ability to communicate, understand, and provide informed consent\n* Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension\n* MRI compatible\n* Intact skin on the hemiparetic arm\n* Ability to sit for three hours.\n\nExclusion Criteria:\n\n* Motor or sensory impairment in the non-affected limb (FMA\\\u003C66, filament \\>3.6)\n* Any brainstem and\u002For cerebellar lesion\n* untreated cardiovascular disease\n* History of neurologic disorder other than stroke that affects the arms\n* Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale\n* Current use of a pacemaker\n* History of seizure\n* Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol\u002Falcohol injections \\\u003C12 months before participation\n* Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes\n* Current participation in any experimental rehabilitation or drug studies\n* Individuals with any known contraindications to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity\n* pregnant women or women who are nursing.\n\nAdditionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in \"Medication Interactions\", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive\u002F antiarrhythmic agents; and hormonal medications\u002Fcontraceptives.",{"count":631,"type":22},64,[633],"EARLY_PHASE1","This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.",[28],[637,638,639,640,31,641,642],"Neurotransmitters","flexion synergy","brain plasticity","tizanidine","motor control","spasticity",{"date":195,"type":38},{"date":645,"type":38},"2024-08-23",{"date":647,"type":22},"2029-07-31",{"name":649,"class":45},"Northwestern University",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":17,"minAge":658,"maxAge":659,"enrollmentInfo":660,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":662,"conditions":663,"keywords":669,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":681,"startDateStruct":682,"completionDateStruct":684,"leadSponsor":686,"locationsCount":46},"100652345","bedside-cranial-ultrasound-for-risk-stratified-imaging-in-pediatric-acute-brain-injury-100652345","NCT07772323","Bedside Cranial Ultrasound for Risk-Stratified Imaging in Pediatric Acute Brain Injury","Bedside Cranial Point-of-Care Ultrasound (cPOCUS) for Risk-Stratified Imaging in Pediatric Acute Brain Injury: A Prospective Diagnostic-Accuracy and Longitudinal Biomarker Cohort Study (CUPID-Peds)","CUPID-Peds","Inclusion Criteria:\n\n* Children 2 to 17 years of age\n* Undergoing a clinically indicated (standard-of-care) head CT for suspected acute brain injury (including trauma, headache with neurologic findings, altered mental status, focal deficit, seizure, post-cardiac-arrest, oncologic neurologic emergency, or intracranial infection)\n* Seen in the pediatric Emergency Department or Pediatric Intensive Care Unit at the Children's Hospital of Richmond at VCU (CHoR-VCU)\n* Consent obtainable from a legally authorized representative (LAR)\n* Cranial ultrasound feasible within the protocol time window (within 6 hours of head CT)\n\nExclusion Criteria:\n\n* Open skull fracture\n* Prior hemicraniectomy\n* Cranial surgical defect at the insonation site\n* Anticipated transition to comfort-only care\n* Any clinical condition in which cranial ultrasound would delay a time-critical intervention","2 Years","17 Years",{"count":661,"type":22},220,"Acute brain injury (ABI) is a leading cause of death and long-term disability in children. Diagnosis depends on fast neuroimaging, and head computed tomography (CT) is the bedside reference standard despite exposing the developing brain to ionizing radiation. A safe, portable, radiation-free bedside tool is needed to help decide which children need a head CT, to speed CT when injury is present, and to safely monitor injured children between scans. This study evaluates B-mode cranial point-of-care ultrasound (cPOCUS) performed through the temporal (and frontal) bone windows in children undergoing a clinically indicated head CT in the pediatric emergency department (ED) and pediatric intensive care unit (PICU). Children's thin skulls provide adequate acoustic windows in more than 95% of cases. cPOCUS is acquired by trained research scanners within 6 hours of head CT and interpreted offline by two blinded expert readers; the radiology CT report is the diagnostic gold standard. This is a prospective observational study; cPOCUS results are not returned to the clinical team in real time and do not change clinical care.",[664,614,665,666,28,667,668],"Acute Brain Injury","Intracranial Hemorrhage","Hydrocephalus","Brain Neoplasm","Hypoxia-Ischemia, Brain",[670,671,672,673,674,675,676,677,678,679],"cranial ultrasound","point-of-care ultrasound","cPOCUS","transcranial B-mode ultrasound","pediatric neuroimaging","head CT","midline shift","diagnostic accuracy","radiation reduction","neurocritical care","2026-08-13",{"date":95,"type":38},{"date":683,"type":22},"2026-11-30",{"date":685,"type":22},"2028-11-30",{"name":687,"class":45},"Virginia Commonwealth University",{"id":689,"slug":690,"hasResults":12,"nctId":691,"briefTitle":692,"officialTitle":693,"acronym":4,"eligibilityCriteria":694,"healthyVolunteers":12,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":695,"targetDuration":4,"studyType":23,"phases":697,"briefSummary":698,"conditions":699,"keywords":700,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":680,"lastUpdatePostDateStruct":703,"startDateStruct":704,"completionDateStruct":706,"leadSponsor":708,"locationsCount":46},"100644977","overground-virtual-reality-vr-gait-rehabilitation-for-stroke-100644977","NCT07676578","Overground Virtual Reality (VR) Gait Rehabilitation for Stroke","Investigating the Feasibility and Translational Therapeutic Benefits of Overground, Fully Immersive Virtual Reality (VR) Gait Rehabilitation Therapies for Stroke Survivors","Inclusion Criteria:\n\n* Diagnosis: Anischemic or hemorrhagic stroke verified by imaging, confirmed by the patient's physician, and 1-6 months post-stroke (subacute phase)\n* Motor Impairment Level: Functional Ambulation Category (FAC) 3-5, showing moderate impairment while still allowing safe participation in gait tasks.\n* Cognitive Function: Mini-Mental State Examination (MMSE) score ≥ 24 or Montreal Cognitive Assessment (MoCA) score \\>= 20, indicating sufficient cognitive function to participate in the study.\n* Exercise Clearance: Approval from a physician for participation in exercise- and VR-based interventions.\n* Rehabilitation Need: 10-Meter Walk Test \\\u003C1.0 m\u002Fs, as timed by a PT during screening, indicating a need for functional rehabilitation.\n* Consent: Must be able to provide informed consent for themselves.\n\nExclusion Criteria:\n\n* Participants with uncontrolled cardiovascular, orthopedic, or metabolic conditions or unstable medication regimens that could interfere with their participation in the study.\n* Any comorbidity that could interfere with walking or gait training.\n* Participation in robot- or VR-assisted gait training within the last 6 months.\n* Intolerance to virtual reality environments or motion simulation.\n* Severe cognitive, visual, or hearing impairments where the participant cannot follow the therapist's instructions.\n* Any other condition deemed unsafe or confounding by investigator, such as pre-existing neurological conditions unrelated to stroke (e.g. Parkinson's, multiple sclerosis), unmanaged pain medications, or acute medical events during the screening period (e.g. recurrent stroke, hospitalization).\n* Individuals who score a 12 or higher on the Disability Rating Scale.\n* Recent Therapy: Participants should not have received physical therapy (PT) within the last month.",{"count":696,"type":22},30,[25],"The purpose of this study is to evaluate a new virtual reality (VR)-based rehabilitation program designed to help stroke survivors improve their walking abilities in real-world settings. By comparing immersive VR-assisted overground gait therapy to contemporary non-immersive, treadmill-based VR therapy (i.e., C-Mill), the investigators aim to determine its effectiveness in enhancing mobility and quality of life for stroke survivors.",[28],[701,702,28],"Gait Training","Virtual Reality",{"date":442,"type":38},{"date":705,"type":22},"2026-08",{"date":707,"type":22},"2027-08",{"name":709,"class":45},"Indiana University"]